Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony S.K. Mok (Coresponding Author), Yi Long Wu, Iveta Kudaba, Dariusz M. Kowalski, Byoung Chul Cho, Hande Z. Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K. Laktionov, Igor Bondarenko, Kaoru Kubota, Gregory M. Lubiniecki, Jin Zhang, Debra Kush, Gilberto Lopes, KEYNOTE-042 Investigators, Gunta Purkalne (Member of the Working Group)

Research output: Contribution to journal › Article › peer-review

1785 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences